2023 World Conference on Lung Cancer (Posters)-EP11.02. Atezolizumab vs Single-Agent Chemo in NSCLC Patients Ineligible for a 1L Platinum Regimen: Asian Subgroup Analysis of IPSOS

EP11.02. Atezolizumab vs Single-Agent Chemo in NSCLC Patients Ineligible for a 1L Platinum Regimen: Asian Subgroup Analysis of IPSOS - PDF(Abstract)

Back to course

Pdf Summary

The study titled "Atezolizumab vs Single-Agent Chemo in NSCLC Patients Ineligible for a 1L Platinum Regimen: Asian Subgroup Analysis of IPSOS" presented the results of a Phase III study that compared the efficacy of atezolizumab to single-agent chemotherapy in Asian patients with metastatic non-small cell lung cancer (NSCLC) who were ineligible for platinum-doublet chemotherapy (PDC).<br /><br />The study, known as IPSOS, included patients with locally advanced or metastatic NSCLC without driver mutations. The patients were randomized to receive atezolizumab or chemotherapy (vinorelbine or gemcitabine) and were followed for a median of 41.0 months.<br /><br />The subgroup analysis included 70 Asian patients from China and Vietnam out of a total of 453 patients in the intention-to-treat population. The analysis showed that the atezolizumab arm had a numerically longer median overall survival (OS) compared to the chemotherapy arm. Atezolizumab also demonstrated a numerically longer median progression-free survival (PFS) and higher 1-year and 2-year OS rates and overall response rate (ORR) compared to chemotherapy.<br /><br />The safety profile of atezolizumab in the Asian subgroup was comparable to the overall study population, with grade 3/4 adverse events occurring in both treatment arms. There were no reported grade 5 adverse events in the chemotherapy arm, but two occurred in the atezolizumab arm.<br /><br />The authors concluded that in this subgroup analysis, atezolizumab monotherapy showed consistent safety and efficacy compared to single-agent chemotherapy in Asian patients with NSCLC who were ineligible for PDC.<br /><br />This study provides important insights into the use of atezolizumab in specific patient populations and highlights its potential as a treatment option for Asian patients with metastatic NSCLC. Further studies are needed to confirm and validate these findings.

Asset Subtitle

Baohui Han

Meta Tag

Speaker Baohui Han

Topic Metastatic NSCLC: Immunotherapy - Prospective

Keywords

atezolizumab

single-agent chemo

NSCLC

Asian subgroup analysis

IPSOS

metastatic non-small cell lung cancer

platinum-doublet chemotherapy

overall survival

progression-free survival

safety and efficacy